We are pleased to announce that Founding Partner Adam Levitt was recently named to Lawdragon’s 2025 list of the 500 Leading Litigators in America.
Lawdragon describes the attorneys recognized on this list as “the best litigators the U.S. has to offer—in antitrust, intellectual property, white collar and investigations, securities and corporate governance litigation, and a vast array of class actions, product liability and other complex civil litigation.”
Adam was selected from among a record number of submissions through “original journalistic research and vetting with the nation’s leading trial lawyers,” Lawdragon states. “These lawyers win hundreds of millions, billions even. They win rights, or lose them. They win freedom, or lose it for someone. They have the abilities to change businesses and entire industries. It’s an audacious thing a trial lawyer does: to tell a judge, jury or other arbiter, ‘Hear me. Believe me. Rule for my client.’”
Adam currently serves as lead or co-lead counsel in a number of high-stakes class action, public client, and multidistrict litigations, including representing the City of Baltimore in response to the catastrophic impact of the Francis Scott Key Bridge collapse, the largest maritime disaster in U.S. history; serving as Interim Co-Lead Counsel in In Re: Oral Phenylephrine Marketing and Sales Practices Litigation, MDL 3089 (E.D.N.Y.), where he represents consumers nationwide in for Defendants’ alleged deceptive and unfair practices in marketing and selling oral decongestant products containing phenylephrine, despite knowing its lack of efficacy; and securities, financial services, and automotive defect litigations and arbitrations against Ford, Honda, Nissan, and Mercedes-Benz. He also represents multiple State Attorneys General to hold some of the world’s largest chemical companies accountable for widespread environmental contamination from their “forever chemicals” known as PFAS (per- and polyfluoroalkyl substances). For the full list of the 2025 Lawdragon 500 Leading Litigators in America, read here.